A new study shows Vytorin, Merck's (MRK) cholesterol-lowering drug, modestly reduces the risk of...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

A new study shows Vytorin, Merck's (MRK) cholesterol-lowering drug, modestly reduces the risk of heart attacks in patients with kidney disease, and Merck says it will seek regulatory approval for the use of Vytorin for kidney patients. The study doesn't resolve broader questions about Vytorin's safety and efficacy.